Training With Mobile Application in Breast Cancer

Breast Cancer Clinical Trial

Official title:

The Effect of E-mobile Education on The Quality of Life in Breast Cancer Women

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04315012
• Other study ID #: Bakircay University
• Status: Completed
• Phase: N/A
• Start date: January 10, 2018
• Est. completion date: April 17, 2018

Study information

• Verified date: March 2020
• Source: Izmir Bakircay University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Endocrine hormonal therapy (EHT) applied to avoid recurrence and metastasis of the breast cancer has also side effects which do not threaten life; however, it does negatively effects quality of life. The objective of this study was to determine the effects on quality of life of a mobile app-based (e-mobile) education for supportive care of patients with breast cancer receiving adjuvant endocrine hormonal therapy. The data were collected to with face to face and/or telephone interviews at 2 time points: prior to the initiation (T0) and after the completion (T1) of mobile app-based education. Patients were received education via mobile app for 12 weeks during which they were contacted in every 15 days; a mobile app-based (e-mobile) education was provided, including information about breast cancer definition, treatment process, symptoms management, adequate nutrition, regular physical activity and coping with stress. In this process, the control group patients were provided with standard care.

Description:

Mobile devices have an increasing role for the patient care and its use in the field of oncology creates promising opportunities for supportive cancer care and patient education. Mobile applications were established for the supportive cancer care but their area of use is limited. Although there are many field specific medical mobile applications, there are few training programs for the benefit of patients. However, these are innovative tools and provide accessibility, individual training and consultancy in order for the patients to be able to cope with side effects of the treatment; thus, improving their quality of life, symptom management and distress.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 64
• Est. completion date: April 17, 2018
• Est. primary completion date: January 17, 2018
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosed with primary breast cancer,

• Non-metastatic,

• Hormone receptor positive (ER positive and/or PR positive)

• For whom adjuvant EHT was implemented at least for three months

Exclusion Criteria:

• Diagnosed with secondary breast cancer,

• Metastatic,

• Hormone receptor negative (ER negative and/or PR negative)

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms

Intervention

Other:
• receive mobile app-based education
to receive mobile app-based education on quality of life of women diagnosed with breast cancer implementation of adjuvant endocrine hormonal therapy.

Locations

Country	Name	City	State
Turkey	Izmir Bakirçay University	Izmir

Sponsors (2)

Lead Sponsor	Collaborator
Izmir Bakircay University	Ege University

Country where clinical trial is conducted

Turkey, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Functional Assessment for the Cancer Treatment - Endocrine Symptoms Quality of Life Scale (FACT-ES QLS)	The scale includes five sub dimensions and total of 46 items measuring the well-being of patients within the course of the last 7 days. There are sub dimensions for each of the following: physical well-being (7 items, 0-28 points), social/family well-being (7 items, 0-28 points), emotional well-being (6 items, 0-24 points), functional well-being (7 items, 0-28 points) and endocrine symptoms (19 items, 0-76 points). Endocrine symptoms' subdimension contains symptoms related to the side effects of EHT. The range of total points of the scale is 0-184. It shows that quality of life increases as total points of the scale increase. It shows that quality of life decreases as total points of the scale decrease.	Change from Baseline Quality of Life at 12 weeks
Primary	National Comprehensive Cancer Network (NCCN) Distress Thermometer	Patients may specify the severity of the distress level they experienced related to their problems, with these numbers, within the course of last 7 days. No distress is specified with "0" point, a severe amount of distress is specified with "10" points.	Change from Baseline Distress at 12 weeks